Klarsen specializes in data marketing for customer winning and engagement. Thanks to its qualified data and proprietary technologies, it allows its customers to increase their marketing performance and net sales. Klarsen disposes of proprietary assets and qualified and reactive databases, in its network of partners and on its own.

Employees

Sector

IT Services & Consulting

More about the company

Quotes

Date	Price	Change	Volume
11/09/26	€0.7700	-4.70%	5,499
10/09/26	€0.8080	-3.81%	11,435
09/09/26	€0.8400	0.00%	1,004
08/09/26	€0.8400	0.00%	1,131
07/09/26	€0.8400	-1.41%	44,038

Real-time Euronext Paris

More quotes

Market Closed - Euronext Paris 18:55:00 11/09/2026 +03			5-day change	1st Jan Change
0.7700 ^EUR	-4.70%		-9.62%	-11.29%

11-03	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2025	CI
30/04/25	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2024	CI

Market Cap	2.88M 3.34M 2.72M 2.47M 4.63M 319M 4.65M 32.35M 12.44M 162M 12.54M 12.26M 513M	P/E 2023	3.28x	P/E 2024	-86x
Enterprise Value	3.96M 4.59M 3.75M 3.4M 6.37M 439M 6.4M 44.5M 17.11M 223M 17.25M 16.87M 705M	EV / Sales 2023	1.67x	EV / Sales 2024	0.82x
Free-Float	99.21%	Yield 2023 *	-	Yield 2024	-

Markets		Quality
Euronext Paris	ALKLA	Real-time
Börse Stuttgart	4YA	Delayed
Deutsche Boerse AG	4YA	Delayed
Boerse Muenchen	4YA	Real-time

11-03	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2025	CI
30/04/25	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2024	CI
16/10/24	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2024	CI
30/04/24	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2023	CI
15/03/24	Acticor Biotech Raises EUR8 Million to Fund Emergency Stroke Treatment Development	MT
07/11/23	Acticor Biotech’s Phase 2/3 Trial for Stroke Drug Combo on Track for 2024 Results	MT
27/10/23	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2023	CI
27/04/23	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2022	CI
09/03/23	Acticor Biotech Secures Funding Until November After EUR12 Million Equity Raise; Stock Sinks 17%	MT
23/12/22	Acticor Biotech Seeks To Meet With US FDA Over Phase 2/3 Study Of Stroke Drug	MT
14/12/22	Twitter to shut down newsletter product Revue next year	RE
06/12/22	Acticor Biotech Wins EU Health Agency Nod For Phase 2/3 Stroke Study Design	MT
05/10/22	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2022	CI

Klarsen Stock

Stocks

ALKLA

FR0011038348

IT Services & Consulting

Valuation : Klarsen

Chart: Klarsen

Latest news : Klarsen

Press Releases : Klarsen

News in other languages : Klarsen

Quotes and Performance

Price Extremes

Managers and Directors : Klarsen

Latest insider transactions

Other IT Services & Consulting

Financials

Company Profile

Quotes

03-03	Klarsen : ALKLA information relative au nombre total de droits de vote et d'actions composant le capital	PU
02-25	Klarsen : ALKLA-Information relative au nombre de droits de vote et actions composant le capital	PU
12-10	Klarsen : ALKLA-Attribution gratuite de BSA	PU
12-09	Klarsen : ALKLA-ACTIVITE 3T2025	PU
11-27	Klarsen : ALKLA-Résultat augmentation de capital	PU

09-08	Klarsen : calendrier de communication
09-08	Klarsen : ALKLA – Klarsen fait évoluer son calendrier de communication financière et rappelle la tenue de ses Assemblées Générales des 29 septembre et 8 octobre 2026 – 08 Septembre 2026
08-27	Klarsen : ALKLA – Présentation webinaire du 27/08/2026 – Support
08-27	Klarsen : Assemblée générale – 29 Septembre 2026
08-19	Bourse : série de résultats en Europe, flambée d'Unitree et puces Nvidia en Chine

1 day	-4.70%
1 week	-9.62%
Current month	-22.22%
1 month	-14.44%
3 months	+102.63%
6 months	-18.09%
Current year	-11.29%

1 week	0.76	0.85
1 month	0.76	1.68
Current year	0.22	1.68
1 year	0.22	1.68
3 years	0.22	3.72
5 years	0.22	4.03
10 years	0.11	5.4

Manager	Title	Age	Since
Brice Gazeau CEO	Chief Executive Officer	-	-
Patrice Coffe DFI	Director of Finance/CFO	57	01/07/2008
Jean-Pierre Domingo CTO	Chief Tech/Sci/R&D Officer	-	01/01/2013

Director	Title	Age	Since
Patrice Coffe BRD	Director/Board Member	57	14/06/2010
Gérard Parrou BRD	Director/Board Member	74	27/06/2014
Frédéric Bartoli BRD	Director/Board Member	-	23/03/2011

Date	Insider	Type	Main position	Quantity	% Market Cap.
3/15/22 A	Parrou Julien	Buy		2,617	0.0790%
2/28/22 A	Julien Parrou-Duboscq	Buy	Chief Executive Officer	3,011	0.0909%
2/28/22 A	Julien Parrou-Duboscq	Buy	Chief Executive Officer	3,000	0.0905%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KLARSEN	-4.70%	-9.62%	-14.44%	-78.25%	2.96M
IBM	+3.96%	+3.58%	-4.00%	+66.30%	229B
SNOWFLAKE INC.	-0.22%	-2.43%	+48.76%	+97.20%	116B
ACCENTURE PLC	+3.37%	-1.51%	-22.91%	-41.60%	113B
TATA CONSULTANCY SERVICES LTD.	-0.15%	-4.48%	-29.76%	-38.54%	83.35B
RELX PLC	-0.76%	-5.53%	-28.05%	-8.94%	58.46B
INFOSYS LIMITED	+0.12%	-8.17%	-31.98%	-30.87%	43.99B
FUJITSU LIMITED	-1.03%	-3.87%	-0.82%	+102.48%	42.35B
NEC CORPORATION	-1.11%	-6.05%	-1.92%	+175.64%	39.17B
HCL TECHNOLOGIES LIMITED	-0.07%	-6.75%	-17.80%	-5.95%	34.16B
Average	-0.06%	-4.48%	-10.29%	+23.75%	75.92B
Weighted average by Cap.	+1.48%	-1.74%	-5.38%	+36.50%

	2023	2024
Net sales	5.03M 5.83M 4.76M 4.31M 8.09M 557M 8.13M 56.52M 21.73M 284M 21.91M 21.43M 896M	6.31M 7.32M 5.98M 5.42M 10.16M 700M 10.21M 70.97M 27.29M 356M 27.51M 26.91M 1.12B
Net income	2.75M 3.19M 2.6M 2.36M 4.43M 305M 4.45M 30.94M 11.9M 155M 11.99M 11.73M 490M	-47.76K -55.44K -45.23K -40.99K -76.91K -5.3M -77.3K -537K -207K -2.69M -208K -204K -8.51M
Net Debt	-634K -736K -601K -545K -1.02M -70.35M -1.03M -7.14M -2.74M -35.79M -2.77M -2.7M -113M	1.08M 1.25M 1.02M 928K 1.74M 120M 1.75M 12.15M 4.67M 60.97M 4.71M 4.61M 193M